CLINICAL APPLICATIONS OF ERYTHROPOIETIN (MEETING ABSTRACT)

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

CLINICAL APPLICATIONS OF ERYTHROPOIETIN (MEETING ABSTRACT)

National Conference on New Oncologic Agents. February 6-8, 1991, Dallas, TX, p. 31, 1991.. Unique Identifier : AIDSLINE ICDB/92678039
Rudnick SA; R.W. Johnson Pharmaceutical Res. Inst., Raritan, NJ 08869-0602

Abstract: Since its introduction to the clinic in 1985, recombinant human erythropoietin has been used in a diverse range of physiologic replacement applications and pharmacologic interventions in the anemic patient (pt) or the surgical subject. The first anemia of renal failure studies conducted in Washington and in England showed remarkably precise dose response curves, with time to response very tightly correlated with dose administered, on a 3x/wk schedule. This schedule was chosen because of convenience to the dialysis pt, but has proven to be a remarkably robust schedule across all indications. Studies in the AIDS population, while not as consistently positive as in renal failure, have shown that in the face of moderately elevated erythropoietin levels, pharmacologic intervention with erythropoietin can correct anemia. The cancer pt falls in an intermediate setting between the 'physiologic replacement' of renal failure pts and the 'pharmacologic intervention' of AIDS pts. Data support that in all cancer populations erythropoietin can be safely administered to pts as long as caution is maintained around the rate of rise of hematocrit and careful monitoring of blood pressure. Interventions in relatively normal subjects about to undergo surgery have shown that erythropoietin can augment the available amount of autologous blood at the time of surgery, through both predeposit storage and increasing the hematocrit more rapidly postoperatively. Data from the series of studies conducted by the RW Johnson Pharmaceutical Research Institute in these settings are presented.

Keywords: Acquired Immunodeficiency Syndrome/*THERAPY Anemia/*THERAPY Blood Pressure Erythropoietin/*THERAPEUTIC USE Hematocrit Hemodialysis/ADVERSE EFFECTS Human Kidney Failure, Chronic/THERAPY Recombinant Proteins/THERAPEUTIC USE ABSTRACT
920228
M9220885

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .